ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

NCT06699576 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

448

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteosarcoma
Soft Tissue Sarcoma (STS)

Interventions

DRUG: HS-20093
DRUG: Anlotinib
DRUG: Epirubicin
DRUG: Adebrelimab

Sponsor

Hansoh BioMedical R&D Company